Bristol Myers Squibb (BMY) is emerging as a compelling value investment within the pharmaceutical sector, boasting a forward P/E ratio of approximately 9.5 and a dividend yield of 4.2%. This positions it favorably against competitors like Johnson & Johnson and Merck, which have significantly higher P/E ratios and lower yields. Despite a projected revenue decline for 2026, Bristol’s consistent revenue generation and a 94-year history of dividend payments highlight its stability.
However, the market remains cautious due to concerns over slowing legacy revenue, particularly from its flagship drug Eliquis, which is facing a patent cliff. Additionally, the company’s substantial debt, exacerbated by its $1.5 billion acquisition of Orbital Therapeutics, raises questions about its financial health. Yet, Bristol’s growth portfolio is thriving, with revenue increasing from $22.6 billion in 2024 to $26.4 billion in 2025, indicating potential for future growth.
For investors, the key takeaway is to monitor how Bristol addresses its legacy revenue challenges while leveraging its growth portfolio. If successful, it could solidify its status as a true value play in the pharmaceutical landscape.
Source: fool.com